Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Obesity- related diseases are linked to elevated levels of inflammation, oxidative stress, and metabolic dysfunction. Methylsulfonylmethane (MSM) is a naturally occurring compound that demonstrates antioxidant and anti-inflammatory effects. Improvements in measures of metabolic health have been observed in mouse models of obesity and type 2 diabetes following MSM treatment. However, the effect of MSM on obesity-related risk factors for disease in humans has not been investigated. Therefore, the purpose of this investigation will be to determine whether MSM supplementation improves metabolic health, and markers of inflammation and oxidative status.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo Control Group | Placebo Comparator | pill capsules containing white rice flour |
|
| Methylsulfonylmethane Group | Active Comparator | pill capsules containing MSM |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| methylsulfonylmethane | Dietary Supplement | 3g per day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline blood glucose at 4, 8, and 16 weeks | 0,4,8,16 weeks | |
| Change from baseline blood cholesterol at 4, 8, and 16 weeks | 0,4,8,16 weeks | |
| Change from baseline blood pressure at 4, 8, and 16 weeks | 0,4,8,16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline insulin at 4, 8, and 16 weeks | 0,4,8,16 weeks | |
| Change from baseline resting metabolic rate at 16 weeks | 0 and 16 weeks | |
| Change from baseline percent body fat at 4, 8, and 16 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lindsey E Miller, Ph.D | Washington State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington State University | Spokane | Washington | 99202 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C025910 | dimethyl sulfone |
Not provided
Not provided
Not provided
Double-blind placebo controlled randomized controlled trial
Not provided
Not provided
Not provided
| placebo | Dietary Supplement | white rice flour |
|
| 0,4,8,16 weeks |
| Change from baseline in waist circumference at 4, 8, and 16 weeks | 0,4,8,16 weeks |
| Change from baseline in blood markers of inflammation and oxidative stress at 4, 8, and 16 weeks | Inflammatory markers will include c-reactive protein, interleukin-6, and Tumor necrosis factor-alpha. Oxidative stress will be determined by total antioxidant capacity assay. | 0,4,8,16 weeks |
| Change from baseline in pulmonary function tests | Pulmonary function tests include forced expiratory volume in 1 second to forced vital capacity ration and slow vital capacity measurement. Expired nitric oxide has also been included as a marker of pulmonary inflammation. | 0, 4, 8, 16 weeks |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |